Cogent Biosciences, Inc. (COGT) Stock Price & How to Invest

Cogent Biosciences is a Waltham, Massachusetts and Boulder, Colorado biotechnology company building precision therapies for genetically defined diseases. Its lead asset, bezuclastinib, is a tyrosine kinase inhibitor designed to hit the KIT D816V mutation and other KIT exon 17 mutations. That single molecule underpins three indications: non-advanced systemic mastocytosis (the SUMMIT trial), advanced systemic mastocytosis (APEX), and gastrointestinal stromal tumors after imatinib, where it is paired with sunitinib (the PEAK trial). Behind bezuclastinib sits an early research portfolio aimed at ErbB2, PI3K alpha, KRAS and JAK2, with CGT4255 and CGT6297 entering Phase 1 in 2026 and IND filings planned for CGT1815 and CGT1145.

The investment picture is unusually concentrated in a short window. As of the first quarter of 2026 the company had two NDAs accepted by the FDA and a third submitted, with a Priority Review PDUFA date of November 30, 2026 for GIST and December 30, 2026 for non-advanced systemic mastocytosis. Cogent ended March 2026 with roughly $866 million in cash and marketable securities, which management says funds operations into 2028 including commercialization, and general and administrative spending has more than doubled year over year as the commercial organization is built ahead of any approval. The stock has moved from about $10 to the low $40s over the past year, so the market has already discounted a good deal of that outcome. There is no product revenue, the trailing net loss is roughly $354 million, and the difference between a launch and a delay is the whole thesis.

Everything routes through one molecule, so a complete response letter, a label restriction or a safety signal on any of the three applications hits the whole company at once. Bezuclastinib's history includes liver enzyme elevations that shaped dosing decisions, and tolerability is exactly what prescribers weigh when an alternative already exists. In systemic mastocytosis that alternative is avapritinib, now inside Sanofi after the Blueprint Medicines acquisition, which brings launch resources Cogent cannot match. The $866 million position funds operations into 2028 on management's plan, but a slower launch or a wider trial program means returning to equity markets, and the company has already used its at-the-market program and issued roughly $223 million of convertible notes. Finally, the stock trades near the top of a 52-week range that starts around $10, which leaves little cushion if any date slips.

12 analysts publish price targets on COGT, averaging $54.25 against a $42.39 price as of August 2026, or +28.0%. The published targets run from $35.00 to $72.00, a moderate spread, and the ratings split 11 buy, 2 hold, 0 sell. Over the last six months there have been 2 raises and 0 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full COGT forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on Cogent Biosciences, Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Three regulatory decisions inside twelve months. Bezuclastinib has an accepted NDA in non-advanced systemic mastocytosis with a December 30, 2026 PDUFA date, an accepted NDA in second-line GIST under Priority Review with a November 30, 2026 date, and a third submission covering advanced systemic mastocytosis filed in mid-2026. The most optimistic published target, $72.00, assumes this works close to its best case.

The case against. Everything routes through one molecule, so a complete response letter, a label restriction or a safety signal on any of the three applications hits the whole company at once. The most pessimistic target, $35.00, is roughly what COGT is worth if this bites instead.

Read the full bull and bear case on COGT, including what would have to change to break either one. Walnut is not an investment adviser.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Cogent Biosciences, Inc.'s investor relations page or your broker.

• Market cap: ~$7.2B
• Revenue (TTM): ~$0 (no approved product)
• Net loss (TTM): ~$354M
• Cash and marketable securities (Mar 31, 2026): ~$866M
• Q1 2026 operating expenses (R&D plus G&A): ~$104M
• Shares outstanding: ~171M

There is no earnings multiple here because there are no earnings and no product sales, so the market is valuing probability-weighted future revenue from bezuclastinib across three indications. Net of roughly $866 million in cash and about $223 million of convertible notes, the enterprise value sits near $6.6 billion, which implies the market already assumes at least one approval and a credible launch. Quarterly cash burn ran near $87 million in the first quarter of 2026 and G&A more than doubled year over year on commercial build-out, so the burn rate rises before any revenue arrives.

Other names that sit close to COGT: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get COGT exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so COGT sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where COGT fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

COGT is a pre-revenue biotech that is one or two FDA decisions away from becoming a commercial company, priced as though those decisions go its way.

Whether COGT is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is COGT a buy or a sell?, and where the stock could go from here in the COGT stock forecast.

For income investors, whether COGT pays a dividend and how the payout looks is covered in does COGT pay a dividend? And to weigh COGT against a peer, read the full side-by-side comparisons: COGT vs SNY and COGT vs NVS.